167 related articles for article (PubMed ID: 2462467)
1. Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation.
Schild H; von Hoegen P; Schirrmacher V
Cancer Immunol Immunother; 1989; 28(1):22-8. PubMed ID: 2462467
[TBL] [Abstract][Full Text] [Related]
2. Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response.
Von Hoegen P; Weber E; Schirrmacher V
Eur J Immunol; 1988 Aug; 18(8):1159-66. PubMed ID: 2970967
[TBL] [Abstract][Full Text] [Related]
3. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
Schirrmacher V; Haas C; Bonifer R; Ertel C
Clin Cancer Res; 1997 Jul; 3(7):1135-48. PubMed ID: 9815793
[TBL] [Abstract][Full Text] [Related]
4. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III. Postoperative activation of tumor-specific CTLP from mice with metastases requires stimulation with the specific antigen plus additional signals.
von Hoegen P; Heicappell R; Griesbach A; Altevogt P; Schirrmacher V
Invasion Metastasis; 1989; 9(2):117-33. PubMed ID: 2785093
[TBL] [Abstract][Full Text] [Related]
5. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta.
von Hoegen P; Zawatzky R; Schirrmacher V
Cell Immunol; 1990 Mar; 126(1):80-90. PubMed ID: 2302742
[TBL] [Abstract][Full Text] [Related]
6. Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN-alpha/beta.
Kaido T; Maury C; Schirrmacher V; Gresser I
Int J Cancer; 1994 May; 57(4):538-43. PubMed ID: 8181857
[TBL] [Abstract][Full Text] [Related]
7. Host CD4+ T lymphocytes are required for the synergistic action of interferon-alpha/beta and adoptively transferred immune cells in the inhibition of visceral ESb metastases.
Kaido TJ; Maury C; Gresser I
Cancer Res; 1995 Dec; 55(24):6133-9. PubMed ID: 8521404
[TBL] [Abstract][Full Text] [Related]
8. Tumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLTC-CML cultures.
Schirrmacher V; Jurianz K; Roth C; Griesbach A; Bonifer R; Zawatzky R
Int J Oncol; 1999 Feb; 14(2):205-15. PubMed ID: 9917494
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects.
Schirrmacher V; Griesbach A; Ahlert T
Int J Oncol; 2001 May; 18(5):945-52. PubMed ID: 11295039
[TBL] [Abstract][Full Text] [Related]
10. Recruitment and activation of tumor-specific immune T cells in situ. CD8+ cells predominate the secondary response in sponge matrices and exert both delayed-type hypersensitivity-like and cytotoxic T lymphocyte activity.
Zangemeister-Wittke U; Kyewski B; Schirrmacher V
J Immunol; 1989 Jul; 143(1):379-85. PubMed ID: 2499633
[TBL] [Abstract][Full Text] [Related]
11. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response.
Zhao L; Mei Y; Sun Q; Guo L; Wu Y; Yu X; Hu B; Liu X; Liu H
J Immunol; 2014 Jul; 193(2):735-45. PubMed ID: 24943214
[TBL] [Abstract][Full Text] [Related]
12. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes.
Schirrmacher V; Bosslet K; Shantz G; Clauer K; Hübsch D
Int J Cancer; 1979 Feb; 23(2):245-52. PubMed ID: 83969
[TBL] [Abstract][Full Text] [Related]
13. Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus.
Haas C; Ertel C; Gerhards R; Schirrmacher V
Int J Oncol; 1998 Dec; 13(6):1105-15. PubMed ID: 9824618
[TBL] [Abstract][Full Text] [Related]
14. Specific eradication of micrometastases by transfer of tumour-immune T cells from major-histocompatibility-complex congenic mice.
Schirrmacher V; von Hoegen P; Griesbach A; Schild HJ; Zangemeister-Wittke U
Cancer Immunol Immunother; 1991; 32(6):373-81. PubMed ID: 1826094
[TBL] [Abstract][Full Text] [Related]
15. Graft-versus-leukemia reactivity involves cluster formation between superantigen-reactive donor T lymphocytes and host macrophages.
Müerköster S; Wachowski O; Zerban H; Schirrmacher V; Umansky V; Rocha M
Clin Cancer Res; 1998 Dec; 4(12):3095-106. PubMed ID: 9865926
[TBL] [Abstract][Full Text] [Related]
16. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity.
Schirrmacher V; Heicappell R
Clin Exp Metastasis; 1987; 5(2):147-56. PubMed ID: 3594972
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric assessment of chicken T cell-mediated immune responses after Newcastle disease virus vaccination and challenge.
Dalgaard TS; Norup LR; Pedersen AR; Handberg KJ; Jørgensen PH; Juul-Madsen HR
Vaccine; 2010 Jun; 28(28):4506-14. PubMed ID: 20434546
[TBL] [Abstract][Full Text] [Related]
18. Prolongation of survival of mice bearing the Eb and ESb lymphoma by treatment with interferon inducers alone or in combination with Corynebacterium parvum.
Storch E; Kirchner H; Schirrmacher V
Cancer Immunol Immunother; 1986; 23(3):179-84. PubMed ID: 2431778
[TBL] [Abstract][Full Text] [Related]
19. Analysis of protective and cytotoxic immune responses in vivo against metabolically inactivated and untreated cells of a mutagenized tumor line (requirements for tumor immunogenicity).
Wehrmaker A; Lehmann V; Dröge W
Cell Immunol; 1986 Sep; 101(2):290-8. PubMed ID: 2428514
[TBL] [Abstract][Full Text] [Related]
20. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
